This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Mucci LA, Hjelmborg JB, Harris JR, Czene K, Havelick DJ, Scheike T, et al. Familial risk and heritability of cancer among twins in Nordic Countries. JAMA. 2016;315:68–76.
Xu J, Sun J, Zheng SL. Prostate cancer risk-associated genetic markers and their potential clinical utility. Asian J Androl. 2013;15:314–22.
National Cancer Institute. The Cancer Data Access System. https://biometry.nci.nih.gov/cdas/. Accessed 24 May 2019.
Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med. 2012;366:141–9.
Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375:443–53.
Na R, Zheng SL, Han M, Yu H, Jiang D, Shah S, et al. Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death. Eur Urol. 2017;71:740–7.
Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2018;50:928–36.
Conran CA, Na R, Chen H, Jiang D, Lin X, Zheng SL, et al. Population-standardized genetic risk score: the SNP-based method of choice for inherited risk assessment of prostate cancer. Asian J Androl. 2016;18:520–4.
Yu H, Shi Z, Wu Y, Wang C-H, Lin X, Perschon C, et al. Concept and benchmarks for assessing narrow-sense validity of genetic risk score values. Prostate. 2019;79:1099–105.
Chen H, Liu X, Brendler CB, Ankerst DP, Leach RJ, Goodman PJ, et al. Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: results from the prostate cancer prevention trial. Prostate. 2016;76:1120–9.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
JX and WI hold an issued US patent “Methods and compositions for correlating genetic markers with PCa risk” (US9732389 B2). The remaining authors declare that they have no conflict of interest.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Xu, J., Labbate, C.V., Isaacs, W.B. et al. Inherited risk assessment of prostate cancer: it takes three to do it right. Prostate Cancer Prostatic Dis 23, 59–61 (2020). https://doi.org/10.1038/s41391-019-0165-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41391-019-0165-y